Investor Relations



We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists more than 30 years ago, our science-driven approach has resulted in eight FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.




  • Nov 30

    Regeneron Announces Investor Webcast at American Society of Hematology 2020 Annual Meeting
  • Nov 30

    Dupixent® (dupilumab) Approved by European Commission as First and Only Biologic Medicine for Children Aged 6 to 11 Years with Severe Atopic Dermatitis


  • Regeneron Oncology Investor Event, ASH 2020
    Dec 7
    4:30 PM EST
    Dec 7, 2020 | 4:30 PM EST

  • Piper Sandler 32nd Annual Virtual Healthcare Conference
    Dec 2
    8:00 AM EST
    Dec 2, 2020 | 8:00 AM EST